Ioxitalamic acid

From WikiMD's Wellness Encyclopedia

Ioxitalamic acid

Ioxitalamic acid, commonly recognized by its brand name Telebrix, is an organoiodine compound specifically engineered for its use as a contrast medium in a multitude of diagnostic radiographic procedures. As an iodinated monomer molecule, ioxitalamic acid's distinguishing feature is its capability to enhance the clarity of medical images by absorbing X-rays more effectively than the tissues in the human body.

Chemical and Physical Properties[edit | edit source]

Ioxitalamic acid, like other members of the iodinated contrast media family, possesses a high iodine content, making it particularly effective at attenuating X-rays. The presence of iodine atoms in these molecules is crucial for their X-ray absorptive properties and hence their utility in radiographic imaging[1].

Clinical Applications[edit | edit source]

Ioxitalamic acid's clinical applications span a wide range of imaging studies:

This contrast agent significantly enhances the contrast between the organ of interest and its surrounding structures, thereby improving the diagnostic accuracy of the imaging study[2].

Pharmacokinetics[edit | edit source]

Post-intravascular administration, ioxitalamic acid quickly disperses into the extracellular fluid space. Predominantly, renal excretion facilitates its removal from the body. Hence, its clearance correlates directly with the renal function, making dosage adjustments necessary for patients with compromised renal function[3].

Safety Profile and Adverse Effects[edit | edit source]

While ioxitalamic acid is generally considered safe for most patients, it's crucial for clinicians to be vigilant for potential adverse reactions. Common side effects encompass:

  • Flushing or warmth at the injection site
  • Mild nausea

Severe reactions, though uncommon, may manifest as:

Such reactions necessitate immediate medical attention, and healthcare providers must be prepared to manage these potential complications[4].

Conclusion[edit | edit source]

Ioxitalamic acid, with its robust contrast-enhancing properties, remains a cornerstone in modern radiological practices. Through its effective differentiation of bodily structures, it offers invaluable assistance in accurate disease diagnosis and assessment.


References[edit | edit source]

  • Cohan, R. H., Dunnick, N. R., & Leder, R. A. (1991). Intravascular contrast material administration in current radiologic practice: a comprehensive overview. Radiology, 180(1), 13-21.
  • Manzke, R., Meyer, B. C., Frenzel, T., & Wedegärtner, U. (2019). Applications of ionic and nonionic contrast media in radiology. Rofo, 191(1), 24-30.
  • Barrett, B. J., & Parfrey, P. S. (2005). Clinical practice. Preventing nephropathy induced by contrast medium. The New England journal of medicine, 352(3), 239-246.
  • Pannu, N., & Wiebe, N. (2008). Prophylaxis strategies for contrast-induced nephropathy. JAMA, 299(23), 2773-2783.
  1. Cohan, R. H., Dunnick, N. R., & Leder, R. A. (1991). Intravascular contrast material administration in current radiologic practice: a comprehensive overview. Radiology, 180(1), 13-21.
  2. Manzke, R., Meyer, B. C., Frenzel, T., & Wedegärtner, U. (2019). Applications of ionic and nonionic contrast media in radiology. Rofo, 191(1), 24-30.
  3. Barrett, B. J., & Parfrey, P. S. (2005). Clinical practice. Preventing nephropathy induced by contrast medium. The New England journal of medicine, 352(3), 239-246.
  4. Pannu, N., & Wiebe, N. (2008). Prophylaxis strategies for contrast-induced nephropathy. JAMA, 299(23), 2773-2783.

Contributors: Prab R. Tumpati, MD